← Back to patent-cliff list
Bleximenib
Tier C — Watch / tradeBleximenib
Janssen Research & Development Llc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KMT2A, MEN1
Indications (approved)：Acute myeloid leukaemia, Leukaemia, Acute lymphoblastic leukaemia
Regional status
US
Phase III
2025-06-04
EU
Phase III
2025-06-04
China
Phase III
2025-06-04
Japan
Phase III
2025-06-04
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bleximenib?
Approved indications include: Acute myeloid leukaemia, Leukaemia, Acute lymphoblastic leukaemia.
When does the Bleximenib patent expire?
No public expiry year is available for Bleximenib yet; this page updates once verified.
How do I get a quote for Bleximenib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30